Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1 Mutation Myeloid Neoplasms”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Early research (Phase 1)Ended earlyNCT04250051
What this trial is testing

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myeloproliferative Neoplasm+5 more
Northwestern University 2
Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Early research (Phase 1)Active Not RecruitingNCT02632708
What this trial is testing

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more
Institut de Recherches Internationales Servier 153
Large-scale testing (Phase 3)Active Not RecruitingNCT03173248
What this trial is testing

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+1 more
Institut de Recherches Internationales Servier 146
Testing effectiveness (Phase 2)WithdrawnNCT04044209
What this trial is testing

The IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Yale University
Testing effectiveness (Phase 2)Looking for participantsNCT06668584
What this trial is testing

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

Who this might be right for
Myeloid Malignancies
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Looking for participantsNCT04493164
What this trial is testing

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Gene MutationsMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more
M.D. Anderson Cancer Center 30
Not applicableApproved For MarketingNCT03245424
What this trial is testing

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Who this might be right for
Acute Myeloid LeukemiaRelapsed Adult AMLRelapsed Pediatric AML
Agios Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07304011
What this trial is testing

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

Who this might be right for
Acute Myeloid Leukemia
University of California, Davis 28
Early research (Phase 1)Looking for participantsNCT06543381
What this trial is testing

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 15
Not applicableStudy completedNCT06181734
What this trial is testing

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

Who this might be right for
Acute Myeloid Leukemia (AML)
iOMEDICO AG 8
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Early research (Phase 1)WithdrawnNCT04955938
What this trial is testing

Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Who this might be right for
IDH MutationIDH1 MutationIDH2 Gene Mutation+2 more
University of Chicago
Not applicableStudy completedNCT02986620
What this trial is testing

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
AML, Adult
Gruppo Italiano Malattie EMatologiche dell'Adulto 388
Testing effectiveness (Phase 2)Looking for participantsNCT07607418
What this trial is testing

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Who this might be right for
AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Ruijin Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03503409
What this trial is testing

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 68
Early research (Phase 1)Study completedNCT03564821
What this trial is testing

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Who this might be right for
IDH1 Mutation Myeloid Neoplasms
Massachusetts General Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT03471260
What this trial is testing

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaHematopoietic and Lymphoid System NeoplasmMyelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 96
Testing effectiveness (Phase 2)Looking for participantsNCT07471841
What this trial is testing

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Who this might be right for
IDH1 MutationRelapsed / Refractory AML
Timothy Pardee 25
Testing effectiveness (Phase 2)WithdrawnNCT04013880
What this trial is testing

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+3 more
Vanderbilt-Ingram Cancer Center
Load More Results